Ulya Badilli
Overview
Explore the profile of Ulya Badilli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amasya G, Sengel TUrk C, Badilli U, Tarimci N
Turk J Pharm Sci
. 2020 Sep;
17(4):359-366.
PMID: 32939130
Objectives: The aim of this study was to develop fluticasone propionate (FP)-loaded solid lipid nanoparticle (SLN) formulations by using factorial design approach. Materials And Methods: Tristearin percentages (X1) (1%, 2%,...
2.
Amasya G, Aksu B, Badilli U, Onay-Besikci A, Tarimci N
Int J Pharm
. 2019 Apr;
563:110-121.
PMID: 30935913
This research attempts to bring together the positive aspects of lipid nanoparticles and Quality by Design (QbD) approach for developing a novel drug delivery system for skin cancers and aktinic...
3.
Amasya G, Gumustas M, Badilli U, Ozkan S, Tarimci N
J Pharm Biomed Anal
. 2018 Mar;
154:285-293.
PMID: 29567571
This is the first report in literature using hydrophilic interaction liquid chromatography (HILIC) in combination with diode array detector (DAD) for stability indicating determination of 5-Fluorouracil (5-FU) from its bulk...
4.
Badilli U, Sengel-Turk C, Amasya G, Tarimci N
Curr Drug Deliv
. 2016 Aug;
14(3):386-393.
PMID: 27501715
Background: Semisolid SLNs are novel strategy for dermal drug administration instead of incorporating the SLN dispersions into conventional semisolids. Etofenamate loaded semisolid SLNs were successfully prepared and in vitro characterization...
5.
Amasya G, Badilli U, Aksu B, Tarimci N
Eur J Pharm Sci
. 2016 Jan;
84:92-102.
PMID: 26780593
With Quality by Design (QbD), a systematic approach involving design and development of all production processes to achieve the final product with a predetermined quality, you work within a design...
6.
Skin Localization of Lipid Nanoparticles (SLN/NLC): Focusing the Influence of Formulation Parameters
Amasya G, Sandri G, Onay-Besikci A, Badilli U, Caramella C, Bonferoni M, et al.
Curr Drug Deliv
. 2016 Jan;
13(7):1100-1110.
PMID: 26725723
Background: In this study, fluorescein labeled SLN and NLC formulations were prepared for improving the dermal distribution of the hydrophilic active ingredients and for enhancing the skin penetration. Methods: To...
7.
Badilli U, Sengel-Turk C, Onay-Besikci A, Tarimci N
Curr Drug Deliv
. 2014 Jun;
12(2):200-9.
PMID: 24925321
Dermal application of various active substances is widely preferred for topical or systemic delivery. SLNs consist of biocompatible and non-toxic lipids and have a great potential for topical application in...
8.
Testa G, Gamba P, Badilli U, Gargiulo S, Maina M, Guina T, et al.
PLoS One
. 2014 May;
9(5):e96795.
PMID: 24802026
Chronic inflammatory events appear to play a fundamental role in Alzheimer's disease (AD)-related neuropathological changes, and to result in neuronal dysfunction and death. The inflammatory responses observed in the AD...
9.
Badilli U, Sen T, Tarimci N
AAPS PharmSciTech
. 2011 Jul;
12(3):949-57.
PMID: 21748539
Psoriasis is a chronic, autoimmune skin disease affecting approximately 2% of the world's population. Clobetasol propionate which is a superpotent topical corticosteroid is widely used for topical treatment of psoriasis....